{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T19:57:33Z","timestamp":1792439853698,"version":"4.5.0"},"reference-count":127,"publisher":"Portland Press Ltd.","issue":"14","content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,7,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>In the past two decades, treatment outcomes for a wide range of malignancies have improved remarkably due to the development of novel anti-cancer therapies, including vascular endothelial growth factor inhibitors (VEGFIs) and immune checkpoint inhibitors (ICIs). Despite their unprecedented anti-tumour effects, it is becoming increasingly clear that both types of agents are associated with specific cardiovascular toxicity, including hypertension, congestive heart failure, myocarditis and acceleration of atherosclerosis. Currently, VEGFI and ICI combination therapy is recommended for the treatment of advanced renal cell carcinoma (RCC) and has shown promising treatment efficacy in other tumour types as well. Consequently, VEGFI and ICI combination therapy will most likely become an important therapeutic strategy for various malignancies. However, this combinatory approach is expected to be accompanied by a substantial increase in cardiovascular risk, as both types of agents could act synergistically to induce cardiovascular sequelae. Therefore, a comprehensive baseline assessment and adequate monitoring by specialised cardio-oncology teams is essential in case these agents are used in combination, particularly in high-risk patients. This review summarises the mechanisms of action and treatment indications for currently registered VEGFIs and ICIs, and discusses their main vascular and cardiac toxicity. Subsequently, we provide the biological rationales for the observed promising synergistic anti-tumour effects of combined VEGFI\/ICI administration. Lastly, we speculate on the increased risk for cardiovascular toxicity in case these agents are used in combination and its implications and future directions for the clinical situation.<\/jats:p>","DOI":"10.1042\/cs20200300","type":"journal-article","created":{"date-parts":[[2021,7,20]],"date-time":"2021-07-20T11:10:47Z","timestamp":1626779447000},"page":"1649-1668","update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Cardiovascular toxicity of angiogenesis inhibitors and immune checkpoint inhibitors: synergistic anti-tumour effects at the cost of increased cardiovascular risk?"],"prefix":"10.1042","volume":"135","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6817-9156","authenticated-orcid":false,"given":"Daan\u00a0C.H.\u00a0van","family":"Dorst","sequence":"first","affiliation":[{"name":"Division of Vascular Medicine and Pharmacology, Department of Internal Medicine, Erasmus MC University Medical Center, Rotterdam, The Netherlands"},{"name":"Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leni\u00a0van","family":"Doorn","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrina\u00a0M.","family":"Mirabito Colafella","sequence":"additional","affiliation":[{"name":"Cardiovascular Disease Program, Biomedicine Discovery Institute and Department of Physiology, Monash University, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier\u00a0C.","family":"Manintveld","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Erasmus MC University Medical Center, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.\u00a0Carlijne","family":"Hassing","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Erasmus MC University Medical Center, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5052-3585","authenticated-orcid":false,"given":"A.H.\u00a0Jan","family":"Danser","sequence":"additional","affiliation":[{"name":"Division of Vascular Medicine and Pharmacology, Department of Internal Medicine, Erasmus MC University Medical Center, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron\u00a0H.J.","family":"Mathijssen","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorie","family":"Versmissen","sequence":"additional","affiliation":[{"name":"Division of Vascular Medicine and Pharmacology, Department of Internal Medicine, Erasmus MC University Medical Center, Rotterdam, The Netherlands"},{"name":"Department of Hospital Pharmacy, Erasmus MC University Medical Center, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"288","published-online":{"date-parts":[[2021,7,20]]},"reference":[{"key":"2021113011224418000_B1","doi-asserted-by":"publisher","first-page":"222","DOI":"10.3322\/caac.20075","article-title":"Angiogenesis inhibitors: current strategies and future prospects","volume":"60","author":"Cook","year":"2010","journal-title":"CA Cancer J. Clin."},{"key":"2021113011224418000_B2","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1002\/jcph.591","article-title":"Immune checkpoint inhibitors: an introduction to the next-generation cancer immunotherapy","volume":"56","author":"Lee","year":"2016","journal-title":"J. Clin. Pharmacol."},{"key":"2021113011224418000_B3","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1016\/j.jacc.2019.07.079","article-title":"Cardiovascular toxicities of immune checkpoint inhibitors: JACC review topic of the week","volume":"74","author":"Ball","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"2021113011224418000_B4","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.jash.2018.03.008","article-title":"Vascular toxicities with VEGF inhibitor therapies-focus on hypertension and arterial thrombotic events","volume":"12","author":"Touyz","year":"2018","journal-title":"J. Am. Soc. Hypertens."},{"key":"2021113011224418000_B5","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1016\/S0140-6736(07)61865-0","article-title":"Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib","volume":"370","author":"Chu","year":"2007","journal-title":"Lancet"},{"key":"2021113011224418000_B6","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"2021113011224418000_B7","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1093\/cvr\/cvz026","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors","volume":"115","author":"Hu","year":"2019","journal-title":"Cardiovasc. Res."},{"key":"2021113011224418000_B8","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in patients treated with immune checkpoint inhibitors","volume":"71","author":"Mahmood","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"2021113011224418000_B9","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"2021113011224418000_B10","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study","volume":"19","author":"Salem","year":"2018","journal-title":"Lancet Oncol."},{"key":"2021113011224418000_B11","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.1161\/CIRCULATIONAHA.120.049981","article-title":"Association between immune checkpoint inhibitors with cardiovascular events and atherosclerotic plaque","volume":"142","author":"Drobni","year":"2020","journal-title":"Circulation"},{"key":"2021113011224418000_B12","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12030738","article-title":"Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence","volume":"12","author":"Vaddepally","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2021113011224418000_B13","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s12943-019-0974-6","article-title":"Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment","volume":"18","author":"Yi","year":"2019","journal-title":"Mol. Cancer"},{"key":"2021113011224418000_B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.11.016","article-title":"Recent eUpdate to the ESMO Clinical Practice Guidelines on renal cell carcinoma on cabozantinib and nivolumab for first-line clear cell renal cancer: Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","author":"Powles","year":"2020","journal-title":"Ann. Oncol."},{"key":"2021113011224418000_B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-021-00496-y","article-title":"Anti-angiogenic agents - overcoming tumour endothelial cell anergy and improving immunotherapy outcomes","author":"Huinen","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2021113011224418000_B16","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/S2213-2600(19)30084-0","article-title":"Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial","volume":"7","author":"Reck","year":"2019","journal-title":"Lancet Respir. Med."},{"key":"2021113011224418000_B17","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1177\/1358863X20910786","article-title":"Vascular medicine and cardio-oncology - a new, evolving clinical frontier","volume":"25","author":"Versmissen","year":"2020","journal-title":"Vasc. Med."},{"key":"2021113011224418000_B18","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1056\/NEJMra1100265","article-title":"Cardiovascular toxic effects of targeted cancer therapies","volume":"375","author":"Moslehi","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"2021113011224418000_B19","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1159\/000088478","article-title":"VEGF as a key mediator of angiogenesis in cancer","volume":"69","author":"Carmeliet","year":"2005","journal-title":"Oncology"},{"key":"2021113011224418000_B20","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1210\/er.2003-0027","article-title":"Vascular endothelial growth factor: basic science and clinical progress","volume":"25","author":"Ferrara","year":"2004","journal-title":"Endocr. Rev."},{"key":"2021113011224418000_B21","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41698-018-0056-z","article-title":"Cardiotoxicity with vascular endothelial growth factor inhibitor therapy","volume":"2","author":"Touyz","year":"2018","journal-title":"NPJ Precis Oncol."},{"key":"2021113011224418000_B22","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1056\/NEJM197111182852108","article-title":"Tumor angiogenesis: therapeutic implications","volume":"285","author":"Folkman","year":"1971","journal-title":"N. Engl. J. Med."},{"key":"2021113011224418000_B23","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"2021113011224418000_B24","doi-asserted-by":"publisher","first-page":"425","DOI":"10.2174\/156652409788167113","article-title":"Hypoxic tumor microenvironment and cancer cell differentiation","volume":"9","author":"Kim","year":"2009","journal-title":"Curr. Mol. Med."},{"key":"2021113011224418000_B25","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.ccell.2014.10.006","article-title":"Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia","volume":"26","author":"Jain","year":"2014","journal-title":"Cancer Cell"},{"key":"2021113011224418000_B26","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/nrclinonc.2018.29","article-title":"Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges","volume":"15","author":"Fukumura","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2021113011224418000_B27","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1042\/CS20200308","article-title":"Vascular toxicity associated with anti-angiogenic drugs","volume":"134","author":"Neves","year":"2020","journal-title":"Clin. Sci. (Lond.)"},{"key":"2021113011224418000_B28","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/nrm.2016.87","article-title":"Mechanisms and regulation of endothelial VEGF receptor signalling","volume":"17","author":"Simons","year":"2016","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"2021113011224418000_B29","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1161\/CIRCRESAHA.121.318051","article-title":"Hypertension and prohypertensive antineoplastic therapies in cancer patients","volume":"128","author":"van Dorst","year":"2021","journal-title":"Circ. Res."},{"key":"2021113011224418000_B30","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","article-title":"2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)","volume":"37","author":"Zamorano","year":"2016","journal-title":"Eur. Heart J."},{"key":"2021113011224418000_B31","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1016\/j.jacc.2015.07.025","article-title":"Vascular and metabolic implications of novel targeted cancer therapies: focus on kinase inhibitors","volume":"66","author":"Li","year":"2015","journal-title":"J. Am. Coll. Cardiol."},{"key":"2021113011224418000_B32","doi-asserted-by":"publisher","first-page":"6250","DOI":"10.1158\/1078-0432.CCR-09-0058","article-title":"Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment","volume":"15","author":"Maitland","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"2021113011224418000_B33","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1161\/HYPERTENSIONAHA.117.10271","article-title":"Mechanisms of VEGF (vascular endothelial growth factor) inhibitor-associated hypertension and vascular disease","volume":"71","author":"Pandey","year":"2018","journal-title":"Hypertension"},{"key":"2021113011224418000_B34","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/clpt.2012.136","article-title":"Polymorphisms in endothelial nitric oxide synthase (eNOS) and vascular endothelial growth factor (VEGF) predict sunitinib-induced hypertension","volume":"92","author":"Eechoute","year":"2012","journal-title":"Clin. Pharmacol. Ther."},{"key":"2021113011224418000_B35","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s11523-011-0201-x","article-title":"Posterior reversible encephalopathy syndrome induced by anti-VEGF agents","volume":"6","author":"Tlemsani","year":"2011","journal-title":"Target Oncol."},{"key":"2021113011224418000_B36","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1093\/qjmed\/hcr139","article-title":"Clinical features and outcomes of posterior reversible encephalopathy syndrome following bevacizumab treatment","volume":"105","author":"Seet","year":"2012","journal-title":"QJM"},{"key":"2021113011224418000_B37","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1093\/cvr\/cvz022","article-title":"Vascular cardio-oncology: vascular endothelial growth factor inhibitors and hypertension","volume":"115","author":"Versmissen","year":"2019","journal-title":"Cardiovasc. Res."},{"key":"2021113011224418000_B38","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1161\/HYPERTENSIONAHA.109.149690","article-title":"Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating endothelin-1 levels","volume":"56","author":"Kappers","year":"2010","journal-title":"Hypertension"},{"key":"2021113011224418000_B39","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1161\/HYPERTENSIONAHA.117.08856","article-title":"Recent advances in hypertension and cardiovascular toxicities with vascular endothelial growth factor inhibition","volume":"70","author":"Touyz","year":"2017","journal-title":"Hypertension"},{"key":"2021113011224418000_B40","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1093\/cvr\/cvz021","article-title":"Microparticles from vascular endothelial growth factor pathway inhibitor-treated cancer patients mediate endothelial cell injury","volume":"115","author":"Neves","year":"2019","journal-title":"Cardiovasc. Res."},{"key":"2021113011224418000_B41","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1161\/HYPERTENSIONAHA.117.10490","article-title":"VEGFR (vascular endothelial growth factor receptor) inhibition induces cardiovascular damage via redox-sensitive processes","volume":"71","author":"Neves","year":"2018","journal-title":"Hypertension"},{"key":"2021113011224418000_B42","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1161\/HYPERTENSIONAHA.111.173559","article-title":"The vascular endothelial growth factor receptor inhibitor sunitinib causes a preeclampsia-like syndrome with activation of the endothelin system","volume":"58","author":"Kappers","year":"2011","journal-title":"Hypertension"},{"key":"2021113011224418000_B43","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1161\/HYPERTENSIONAHA.120.16454","article-title":"Mechanisms Underlying vascular endothelial growth factor receptor inhibition-induced hypertension: The HYPAZ Trial","volume":"77","author":"M\u00e4ki-Pet\u00e4j\u00e4","year":"2021","journal-title":"Hypertension"},{"key":"2021113011224418000_B44","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1161\/HYPERTENSIONAHA.111.182220","article-title":"Sunitinib-induced systemic vasoconstriction in swine is endothelin mediated and does not involve nitric oxide or oxidative stress","volume":"59","author":"Kappers","year":"2012","journal-title":"Hypertension"},{"key":"2021113011224418000_B45","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.ejca.2009.11.001","article-title":"VEGF signalling inhibition-induced proteinuria: mechanisms, significance and management","volume":"46","author":"Izzedine","year":"2010","journal-title":"Eur. J. Cancer"},{"key":"2021113011224418000_B46","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1161\/HYPERTENSIONAHA.114.04187","article-title":"Treatment of hypertension and renal injury induced by the angiogenesis inhibitor sunitinib: preclinical study","volume":"64","author":"Lankhorst","year":"2014","journal-title":"Hypertension"},{"key":"2021113011224418000_B47","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1161\/HYPERTENSIONAHA.116.08565","article-title":"Salt sensitivity of angiogenesis inhibition-induced blood pressure rise: role of interstitial sodium accumulation?","volume":"69","author":"Lankhorst","year":"2017","journal-title":"Hypertension"},{"key":"2021113011224418000_B48","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1056\/NEJMoa055352","article-title":"Soluble endoglin and other circulating antiangiogenic factors in preeclampsia","volume":"355","author":"Levine","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"2021113011224418000_B49","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1056\/NEJMoa1704559","article-title":"Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia","volume":"377","author":"Rolnik","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"2021113011224418000_B50","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1093\/cvr\/cvz260","article-title":"Selective ETA versus dual ETA\/B receptor blockade for the prevention of sunitinib-induced hypertension and albuminuria in WKY rats","volume":"116","author":"Mirabito Colafella","year":"2019","journal-title":"Cardiovasc. Res."},{"key":"2021113011224418000_B51","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1093\/jnci\/djr128","article-title":"Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib","volume":"103","author":"Rini","year":"2011","journal-title":"J. Natl. Cancer Inst."},{"key":"2021113011224418000_B52","doi-asserted-by":"publisher","first-page":"3180","DOI":"10.1093\/annonc\/mds179","article-title":"Hypertension as a potential biomarker of efficacy in patients with gastrointestinal stromal tumor treated with sunitinib","volume":"23","author":"George","year":"2012","journal-title":"Ann. Oncol."},{"key":"2021113011224418000_B53","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1634\/theoncologist.2012-0339","article-title":"Analysis of early hypertension and clinical outcome with bevacizumab: results from seven phase III studies","volume":"18","author":"Hurwitz","year":"2013","journal-title":"Oncologist"},{"key":"2021113011224418000_B54","doi-asserted-by":"publisher","first-page":"2615","DOI":"10.1016\/j.ejca.2015.08.002","article-title":"Hypertension (HTN) as a potential biomarker of efficacy in pazopanib-treated patients with advanced non-adipocytic soft tissue sarcoma. A retrospective study based on European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 trials","volume":"51","author":"Duffaud","year":"2015","journal-title":"Eur. J. Cancer"},{"key":"2021113011224418000_B55","doi-asserted-by":"publisher","first-page":"6152","DOI":"10.1200\/JCO.2009.22.2273","article-title":"Effective strategies for management of hypertension after vascular endothelial growth factor signaling inhibition therapy: results from a phase II randomized, factorial, double-blind study of Cediranib in patients with advanced solid tumors","volume":"27","author":"Langenberg","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"2021113011224418000_B56","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","article-title":"2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)","volume":"37","author":"Zamorano","year":"2016","journal-title":"Eur. Heart J."},{"key":"2021113011224418000_B57","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1093\/jnci\/djq091","article-title":"Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors","volume":"102","author":"Maitland","year":"2010","journal-title":"J. Natl. Cancer Inst."},{"key":"2021113011224418000_B58","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMp030086","article-title":"Cancer-associated thrombosis","volume":"349","author":"Bick","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"2021113011224418000_B59","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1093\/jnci\/djm086","article-title":"Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab","volume":"99","author":"Scappaticci","year":"2007","journal-title":"J. Natl. Cancer Inst."},{"key":"2021113011224418000_B60","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1200\/JCO.2009.27.2757","article-title":"Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials","volume":"28","author":"Choueiri","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"2021113011224418000_B61","doi-asserted-by":"publisher","first-page":"287","DOI":"10.3109\/02841860903524396","article-title":"Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials","volume":"49","author":"Ranpura","year":"2010","journal-title":"Acta Oncol."},{"key":"2021113011224418000_B62","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1001\/jama.2008.656","article-title":"Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis","volume":"300","author":"Nalluri","year":"2008","journal-title":"JAMA"},{"key":"2021113011224418000_B63","doi-asserted-by":"publisher","first-page":"3499","DOI":"10.1200\/JCO.2012.42.8201","article-title":"Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen","volume":"30","author":"Van Cutsem","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"2021113011224418000_B64","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1200\/JCO.2010.32.3220","article-title":"Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies","volume":"29","author":"Hurwitz","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"2021113011224418000_B65","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1177\/2047487318755193","article-title":"Cardiovascular diseases in patients receiving small molecules with anti-vascular endothelial growth factor activity: A meta-analysis of approximately 29,000 cancer patients","volume":"25","author":"Totzeck","year":"2018","journal-title":"Eur. J. Prev. Cardiol."},{"key":"2021113011224418000_B66","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.ctrv.2016.12.002","article-title":"Cardiovascular toxicity of angiogenesis inhibitors in treatment of malignancy: a systematic review and meta-analysis","volume":"53","author":"Abdel-Qadir","year":"2017","journal-title":"Cancer Treat. Rev."},{"key":"2021113011224418000_B67","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/s41569-020-0347-2","article-title":"Vascular toxic effects of cancer therapies","volume":"17","author":"Herrmann","year":"2020","journal-title":"Nat. Rev. Cardiol."},{"key":"2021113011224418000_B68","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.2174\/138945006778559111","article-title":"The many antithrombotic actions of nitric oxide","volume":"7","author":"Tziros","year":"2006","journal-title":"Curr. Drug Targets"},{"key":"2021113011224418000_B69","doi-asserted-by":"publisher","first-page":"9904","DOI":"10.1074\/jbc.M412017200","article-title":"Vascular endothelial growth factor (VEGF)-A165-induced prostacyclin synthesis requires the activation of VEGF receptor-1 and -2 heterodimer","volume":"280","author":"Neagoe","year":"2005","journal-title":"J. Biol. Chem."},{"key":"2021113011224418000_B70","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s12943-015-0418-x","article-title":"Bevacizumab promotes venous thromboembolism through the induction of PAI-1 in a mouse xenograft model of human lung carcinoma","volume":"14","author":"Chen","year":"2015","journal-title":"Mol. Cancer"},{"key":"2021113011224418000_B71","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1111\/j.1538-7836.2008.03212.x","article-title":"Bevacizumab immune complexes activate platelets and induce thrombosis in FCGR2A transgenic mice","volume":"7","author":"Meyer","year":"2009","journal-title":"J. Thromb. Haemost."},{"key":"2021113011224418000_B72","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1161\/ATVBAHA.113.302998","article-title":"Antiangiogenic therapy inhibits venous thrombus resolution","volume":"34","author":"Evans","year":"2014","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"2021113011224418000_B73","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1042\/CS20200305","article-title":"Cardiotoxic effects of angiogenesis inhibitors","volume":"135","author":"Dobbin","year":"2021","journal-title":"Clin. Sci. (Lond.)"},{"key":"2021113011224418000_B74","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1161\/01.HYP.0000215207.54689.31","article-title":"Vascular endothelial growth factor blockade promotes the transition from compensatory cardiac hypertrophy to failure in response to pressure overload","volume":"47","author":"Izumiya","year":"2006","journal-title":"Hypertension"},{"key":"2021113011224418000_B75","doi-asserted-by":"publisher","first-page":"3601","DOI":"10.1158\/1078-0432.CCR-16-2869","article-title":"Prospective evaluation of sunitinib-induced cardiotoxicity in patients with metastatic renal cell carcinoma","volume":"23","author":"Narayan","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"2021113011224418000_B76","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.jchf.2012.09.001","article-title":"The frequency and severity of cardiovascular toxicity from targeted therapy in advanced renal cell carcinoma patients","volume":"1","author":"Hall","year":"2013","journal-title":"JACC Heart Fail."},{"key":"2021113011224418000_B77","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1200\/JCO.2010.31.9129","article-title":"Congestive heart failure risk in patients with breast cancer treated with bevacizumab","volume":"29","author":"Choueiri","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"2021113011224418000_B78","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1038\/bjc.2015.82","article-title":"Incidence and relevance of QTc-interval prolongation caused by tyrosine kinase inhibitors","volume":"112","author":"Kloth","year":"2015","journal-title":"Br. J. Cancer"},{"key":"2021113011224418000_B79","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1002\/ejhf.1957","article-title":"Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC)","volume":"22","author":"\u010celutkien\u0117","year":"2020","journal-title":"Eur. J. Heart Fail."},{"key":"2021113011224418000_B80","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1002\/ejhf.1920","article-title":"Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society","volume":"22","author":"Lyon","year":"2020","journal-title":"Eur. J. Heart Fail."},{"key":"2021113011224418000_B81","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1002\/ehf2.12551","article-title":"Recent advances in cardio-oncology: a report from the \u2018Heart Failure Association 2019 and World Congress on Acute Heart Failure 2019\u2019","volume":"6","author":"Anker","year":"2019","journal-title":"ESC Heart Fail."},{"key":"2021113011224418000_B82","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1002\/ejhf.2017","article-title":"Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology","volume":"22","author":"Pudil","year":"2020","journal-title":"Eur. J. Heart Fail."},{"key":"2021113011224418000_B83","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.annonc.2019.10.023","article-title":"Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations","volume":"31","author":"Curigliano","year":"2020","journal-title":"Ann. Oncol."},{"key":"2021113011224418000_B84","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.ejca.2017.06.028","article-title":"Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017","volume":"83","author":"Ugurel","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"2021113011224418000_B85","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/d41586-018-06751-0","article-title":"Cancer immunologists scoop medicine Nobel prize","volume":"562","author":"Ledford","year":"2018","journal-title":"Nature"},{"key":"2021113011224418000_B86","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jaccao.2020.11.012","article-title":"The evolving immunotherapy landscape and the epidemiology, diagnosis, and management of cardiotoxicity","volume":"3","author":"Zhang","year":"2021","journal-title":"JACC Cardio Oncol."},{"key":"2021113011224418000_B87","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1126\/science.291.5502.319","article-title":"Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice","volume":"291","author":"Nishimura","year":"2001","journal-title":"Science"},{"key":"2021113011224418000_B88","doi-asserted-by":"publisher","first-page":"4735","DOI":"10.1158\/1078-0432.CCR-18-4083","article-title":"Myocarditis in cynomolgus monkeys following treatment with immune checkpoint inhibitors","volume":"25","author":"Ji","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"2021113011224418000_B89","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1161\/CIRCULATIONAHA.118.034497","article-title":"Myocarditis in the setting of cancer therapeutics: proposed case definitions for emerging clinical syndromes in cardio-oncology","volume":"140","author":"Bonaca","year":"2019","journal-title":"Circulation"},{"key":"2021113011224418000_B90","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"2021113011224418000_B91","doi-asserted-by":"publisher","first-page":"e013757","DOI":"10.1161\/JAHA.119.013757","article-title":"Immune checkpoint inhibitor myocarditis: pathophysiological characteristics, diagnosis, and treatment","volume":"9","author":"Palaskas","year":"2020","journal-title":"J. Am. Heart Assoc."},{"key":"2021113011224418000_B92","doi-asserted-by":"publisher","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann. Oncol."},{"key":"2021113011224418000_B93","doi-asserted-by":"publisher","first-page":"2579","DOI":"10.1007\/s10067-018-4177-0","article-title":"Vasculitis associated with immune checkpoint inhibitors-a systematic review","volume":"37","author":"Daxini","year":"2018","journal-title":"Clin. Rheumatol."},{"key":"2021113011224418000_B94","doi-asserted-by":"publisher","first-page":"H1052","DOI":"10.1152\/ajpheart.00024.2017","article-title":"Immune checkpoint dysfunction in large and medium vessel vasculitis","volume":"312","author":"Watanabe","year":"2017","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"2021113011224418000_B95","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1038\/nm.2538","article-title":"Atherosclerosis: current pathogenesis and therapeutic options","volume":"17","author":"Weber","year":"2011","journal-title":"Nat. Med."},{"key":"2021113011224418000_B96","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1161\/CIRCRESAHA.117.312465","article-title":"Trained innate immunity as a novel mechanism linking infection and the development of atherosclerosis","volume":"122","author":"Leentjens","year":"2018","journal-title":"Circ. Res."},{"key":"2021113011224418000_B97","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1038\/nrneph.2017.51","article-title":"The immunology of atherosclerosis","volume":"13","author":"Gistera","year":"2017","journal-title":"Nat. Rev. Nephrol."},{"key":"2021113011224418000_B98","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1016\/j.jacc.2009.09.009","article-title":"Inflammation in atherosclerosis: from pathophysiology to practice","volume":"54","author":"Libby","year":"2009","journal-title":"J. Am. Coll. Cardiol."},{"key":"2021113011224418000_B99","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"2021113011224418000_B100","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.jacc.2012.10.027","article-title":"Low-dose colchicine for secondary prevention of cardiovascular disease","volume":"61","author":"Nidorf","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"2021113011224418000_B101","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1056\/NEJMoa2021372","article-title":"Colchicine in patients with chronic coronary disease","volume":"383","author":"Nidorf","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"2021113011224418000_B102","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1093\/cvr\/cvx248","article-title":"Exploring immune checkpoints as potential therapeutic targets in atherosclerosis","volume":"114","author":"Kusters","year":"2018","journal-title":"Cardiovasc. Res."},{"key":"2021113011224418000_B103","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1161\/ATVBAHA.111.224709","article-title":"Impairment of the programmed cell death-1 pathway increases atherosclerotic lesion development and inflammation","volume":"31","author":"Bu","year":"2011","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"2021113011224418000_B104","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1038\/nrclinonc.2018.9","article-title":"Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa","volume":"15","author":"Khan","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2021113011224418000_B105","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1038\/s12276-020-00500-y","article-title":"Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity","volume":"52","author":"Lee","year":"2020","journal-title":"Exp. Mol. Med."},{"key":"2021113011224418000_B106","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","article-title":"Avelumab plus Axitinib versus Sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Motzer","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"2021113011224418000_B107","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC","volume":"378","author":"Socinski","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"2021113011224418000_B108","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.3389\/fimmu.2020.01956","article-title":"Anti-angiogenic agents in combination with immune checkpoint inhibitors: a promising strategy for cancer treatment","volume":"11","author":"Song","year":"2020","journal-title":"Front. Immunol."},{"key":"2021113011224418000_B109","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1016\/S0140-6736(20)32598-8","article-title":"Enhancing anti-tumour efficacy with immunotherapy combinations","volume":"397","author":"Meric-Bernstam","year":"2021","journal-title":"Lancet North Am. Ed."},{"key":"2021113011224418000_B110","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.ejca.2019.06.021","article-title":"Acute vascular events as a possibly related adverse event of immunotherapy: a single-institute retrospective study","volume":"120","author":"Bar","year":"2019","journal-title":"Eur. J. Cancer"},{"key":"2021113011224418000_B111","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus Bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"2021113011224418000_B112","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jaccao.2019.11.013","article-title":"Immune checkpoint inhibitor-related adverse cardiovascular events in patients with lung cancer","volume":"1","author":"Chitturi","year":"2019","journal-title":"JACC Cardio Oncol."},{"key":"2021113011224418000_B113","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1016\/j.ijcard.2013.03.010","article-title":"Systemic VEGF inhibition accelerates experimental atherosclerosis and disrupts endothelial homeostasis\u2013implications for cardiovascular safety","volume":"168","author":"Winnik","year":"2013","journal-title":"Int. J. Cardiol."},{"key":"2021113011224418000_B114","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1016\/S0140-6736(20)30934-X","article-title":"Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF(V600) mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial","volume":"395","author":"Gutzmer","year":"2020","journal-title":"Lancet"},{"key":"2021113011224418000_B115","doi-asserted-by":"publisher","first-page":"e198890","DOI":"10.1001\/jamanetworkopen.2019.8890","article-title":"Cardiovascular adverse events associated with BRAF and MEK inhibitors: a systematic review and meta-analysis","volume":"2","author":"Mincu","year":"2019","journal-title":"JAMA Netw. Open"},{"key":"2021113011224418000_B116","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s12471-018-1148-7","article-title":"Cardio-oncology: an overview on outpatient management and future developments","volume":"26","author":"Teske","year":"2018","journal-title":"Neth. Heart J."},{"key":"2021113011224418000_B117","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/j.mayocp.2014.05.013","article-title":"Evaluation and management of patients with heart disease and cancer: cardio-oncology","volume":"89","author":"Herrmann","year":"2014","journal-title":"Mayo Clin. Proc."},{"key":"2021113011224418000_B118","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/nrcardio.2013.129","article-title":"Cardiac troponin level elevations not related to acute coronary syndromes","volume":"10","author":"Giannitsis","year":"2013","journal-title":"Nat. Rev. Cardiol."},{"key":"2021113011224418000_B119","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.cjca.2014.02.011","article-title":"Hypertension due to antiangiogenic cancer therapy with vascular endothelial growth factor inhibitors: understanding and managing a new syndrome","volume":"30","author":"Small","year":"2014","journal-title":"Can. J. Cardiol."},{"key":"2021113011224418000_B120","doi-asserted-by":"publisher","first-page":"3124","DOI":"10.1158\/1078-0432.CCR-07-4783","article-title":"Inhibition of vascular endothelial growth factor-a signaling induces hypertension: examining the effect of cediranib (recentin; AZD2171) treatment on blood pressure in rat and the use of concomitant antihypertensive therapy","volume":"14","author":"Curwen","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"2021113011224418000_B121","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.jaccao.2019.11.009","article-title":"Hypertension in cancer patients and survivors: epidemiology, diagnosis, and management","volume":"1","author":"Cohen","year":"2019","journal-title":"JACC Cardio Oncol."},{"key":"2021113011224418000_B122","doi-asserted-by":"publisher","first-page":"5204","DOI":"10.1200\/JCO.2007.15.6331","article-title":"Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma","volume":"26","author":"Schmidinger","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"2021113011224418000_B123","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1136\/heartjnl-2018-313726","article-title":"Toxicity of cancer therapy: what the cardiologist needs to know about angiogenesis inhibitors","volume":"104","author":"Dobbin","year":"2018","journal-title":"Heart"},{"key":"2021113011224418000_B124","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1001\/jama.2018.20578","article-title":"Association of aspirin use for primary prevention with cardiovascular events and bleeding events: a systematic review and meta-analysis","volume":"321","author":"Zheng","year":"2019","journal-title":"JAMA"},{"key":"2021113011224418000_B125","doi-asserted-by":"publisher","first-page":"S26","DOI":"10.1053\/j.seminoncol.2006.08.001","article-title":"Bevacizumab in the treatment of metastatic colorectal cancer: safety profile and management of adverse events","volume":"33","author":"Hurwitz","year":"2006","journal-title":"Semin. Oncol."},{"key":"2021113011224418000_B126","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1016\/j.cell.2015.08.015","article-title":"Cyclooxygenase-dependent tumor growth through evasion of immunity","volume":"162","author":"Zelenay","year":"2015","journal-title":"Cell"},{"key":"2021113011224418000_B127","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001361","article-title":"Integrated analysis of concomitant medications and oncological outcomes from PD-1\/PD-L1 checkpoint inhibitors in clinical practice","volume":"8","author":"Cortellini","year":"2020","journal-title":"J. Immunother. Cancer"}],"container-title":["Clinical Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/portlandpress.com\/clinsci\/article-pdf\/135\/14\/1649\/916890\/cs-2020-0300c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/portlandpress.com\/clinsci\/article-pdf\/135\/14\/1649\/916890\/cs-2020-0300c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T12:18:58Z","timestamp":1638274738000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/clinsci\/article\/135\/14\/1649\/229280\/Cardiovascular-toxicity-of-angiogenesis-inhibitors"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":127,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2021,7,30]]}},"URL":"https:\/\/doi.org\/10.1042\/cs20200300","relation":{},"ISSN":["0143-5221","1470-8736"],"issn-type":[{"value":"0143-5221","type":"print"},{"value":"1470-8736","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,7]]},"published":{"date-parts":[[2021,7]]}}}